Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II osimertinib in poor performance status EGFR T790M-positive NSCLC
jRCT1041180081Phase 2Completed
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC). Primary endpoint: Progression-free survival. Started Aug 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1041180081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041180081.